|
Research & Development
> Fruits of Research
Fruits of Research
 All the drugs which SERVIER introduces stem from its own research.
This is uncommon for a pharmaceutical company. SERVIER aims to develop innovative and novel drugs which address major public health problems and provide objective therapeutic benefit.
The main lines pursued by SERVIER Research are in:
- Cardiovascular diseases
- Central nervous system and psychiatry
- Oncology
- Diabetes and metabolism
- Rheumatology
78 new R&D projects are in progress in these therapeutic areas.
32 projects of research.
38 drugs are currently under development in SERVIER research centres in France and worldwide:
- 13 in preclinical development
- 25 in clinical development, including
- 11 in Phase 1
- 8 in Phase 2
- 4 in Phase 3
- 2 undergoing registration
8 projects on drugs undergoing registration
In 2006
Cardiovascular Disease
Marketing authorisation obtained in Australia for Coralan, a novel bradycardic agent for the treatment of angina .
In 2007
Osteoporosis
Protos, Servier's treatment for post menopausal osteoporosis was approved for PBS listing April 2007.
|
print
